BCM
AEON icon

Bridgeway Capital Management’s AEON Biopharma AEON Stock Holding History

Bridgeway Capital Management’s Portfolio AEON Stock Details AEON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-694
Closed -$27K – 1174
2024
Q4 		$27K Buy
+694
New +$40.4K ﹤0.01% 1178

Other funds holding AEON

DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
DCM
Dupont Capital Management Wilmington, Delaware $2.18M AUM 50.81% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Bridgeway Capital Management's AEON Position: Q1 2025 in Review

Bridgeway Capital Management sold out of AEON Biopharma (AEON) in Q1 2025, closing a stake of 694 shares — an estimated $27K sold.

Bridgeway Capital Management first reported a position in AEON in Q4 2024 and held it in 1 quarter. The position peaked at $27K in Q4 2024. 16 funds tracked by Wall St. Rank hold AEON as of Q1 2025.

  • Bridgeway Capital Management reported no remaining AEON Biopharma position as of Q1 2025 after selling out during the quarter.
  • Bridgeway Capital Management sold 694 AEON Biopharma shares in Q1 2025, an estimated $27K.
  • Bridgeway Capital Management first reported a position in AEON Biopharma in Q4 2024 and held it in 1 quarter.
  • Bridgeway Capital Management's AEON Biopharma position peaked at $27K in Q4 2024.
  • 16 funds tracked by Wall St. Rank held AEON Biopharma as of Q1 2025.

Based on Bridgeway Capital Management's 13F filing for Q1 2025, filed 15 May 2025.